Last reviewed · How we verify

Ananxyl — Competitive Intelligence Brief

Ananxyl (ALPIDEM) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: alpidem. Area: Neuroscience.

marketed alpidem Translocator protein Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Ananxyl (ALPIDEM).

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ananxyl TARGET ALPIDEM marketed alpidem Translocator protein
NE3107 NE3107 BioVie Inc. phase 3 TSPO inhibitor TSPO (translocator protein, 18 kDa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (alpidem class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ananxyl — Competitive Intelligence Brief. https://druglandscape.com/ci/alpidem. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: